Literature DB >> 33801484

When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.

Nicolas Bonadies1,2, Alicia Rovó1, Naomi Porret1, Ulrike Bacher1.   

Abstract

Thrombocytopenia can arise from various conditions, including myelodysplastic syndromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral blood smear, identification of accompanying clinical conditions, and characterization of the clinical course are important for initial assessment of unexplained thrombocytopenia. Increased awareness is required to identify patients with suspected MDS or BMF, who are in need of further investigations by a step-wise approach. Bone marrow cytomorphology, histopathology, and cytogenetics are complemented by myeloid next-generation sequencing (NGS) panels. Such panels are helpful to distinguish reactive cytopenia from clonal conditions. MDS are caused by mutations in the hematopoietic stem/progenitor cells, characterized by cytopenia and dysplasia, and an inherent risk of leukemic progression. Aplastic anemia (AA), the most frequent acquired BMF, is immunologically driven and characterized by an empty bone marrow. Diagnosis remains challenging due to overlaps with other hematological disorders. Congenital BMF, certainly rare in adulthood, can present atypically with thrombocytopenia and can be misdiagnosed. Analyses for chromosome fragility, telomere length, and germline gene sequencing are needed. Interdisciplinary expert teams contribute to diagnosis, prognostication, and choice of therapy for patients with suspected MDS and BMF. With this review we aim to increase the awareness and provide practical approaches for diagnosis of these conditions in suspicious cases presenting with thrombocytopenia.

Entities:  

Keywords:  aplastic anemia (AA); bone marrow failure (BMF) syndromes; myelodysplastic syndromes (MDS); next-generation sequencing (NGS); thrombocytopenia

Year:  2021        PMID: 33801484      PMCID: PMC7958851          DOI: 10.3390/jcm10051026

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  109 in total

1.  Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

Authors:  R T Calado; J N Cooper; H M Padilla-Nash; E M Sloand; C O Wu; P Scheinberg; T Ried; N S Young
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

2.  Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.

Authors:  B Kipfer; T Daikeler; S Kuchen; M Hallal; N Andina; R Allam; N Bonadies
Journal:  Semin Hematol       Date:  2018-05-28       Impact factor: 3.851

Review 3.  Myelodysplastic syndromes: the complexity of stem-cell diseases.

Authors:  Seth J Corey; Mark D Minden; Dwayne L Barber; Hagop Kantarjian; Jean C Y Wang; Aaron D Schimmer
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 4.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

5.  Microarray-based comparative genomic hybridisation reveals additional recurrent aberrations in adult patients evaluated for myelodysplastic syndrome with normal karyotype.

Authors:  Ines Ouahchi; Luduo Zhang; Ramon Benitez Brito; Rudolf Benz; Rouven Müller; Nicolas Bonadies; Joëlle Tchinda
Journal:  Br J Haematol       Date:  2018-01-09       Impact factor: 6.998

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

7.  Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.

Authors:  Mikkael A Sekeres; W Marieke Schoonen; Hagop Kantarjian; Alan List; Jon Fryzek; Ronald Paquette; Jaroslaw P Maciejewski
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

8.  Ileal mass-like lesion induced by Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with aplastic anemia.

Authors:  Kyueng-Whan Min; Ho Young Jung; Hye Seung Han; Tae Sook Hwang; Sung-Yong Kim; Wan Seop Kim; So Dug Lim; Wook Youn Kim
Journal:  APMIS       Date:  2014-09-22       Impact factor: 3.205

9.  Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Marilyn M Li; Elizabeth Chao; Edward D Esplin; David T Miller; Katherine L Nathanson; Sharon E Plon; Maren T Scheuner; Douglas R Stewart
Journal:  Genet Med       Date:  2020-04-23       Impact factor: 8.822

10.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05
View more
  1 in total

1.  Carica papaya ameliorates thrombocytopenia through upregulation of Interleukin-11 and modulation of thrombopoietin in mouse model of carboplatin-induced myelosuppression.

Authors:  Sabeen Irshad; Arham Shabbir; Hina Aslam; Tasleem Akhtar; Muhammad Shahzad
Journal:  Mol Biol Rep       Date:  2022-03-17       Impact factor: 2.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.